{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:07:25Z","timestamp":1791461245372,"version":"4.3.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40265-024-02087-4","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T03:31:21Z","timestamp":1725593481000},"page":"1313-1318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Donanemab: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"issue":"6","key":"2087_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"18","key":"2087_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"key":"2087_CR3","unstructured":"Eli Lilly and Company. Lilly's Kisunla\u2122 (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer's disease [media release]. 2 Jul 2024. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early."},{"key":"2087_CR4","unstructured":"Eli Lilly and Company. KISUNLA (donanemab-azbt) injection, for intravenous use: US prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf. Accessed 15 Aug 2024."},{"issue":"6","key":"2087_CR5","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/cpt.2875","volume":"113","author":"I Gueorguieva","year":"2023","unstructured":"Gueorguieva I, Willis BA, Chua L, et al. Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer\u2019s disease. Clin Pharmacol Ther. 2023;113(6):1258\u201367.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2087_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40120-024-00604-x","volume":"13","author":"S Sato","year":"2024","unstructured":"Sato S, Hatakeyama N, Fujikoshi S, et al. Donanemab in Japanese patients with early Alzheimer\u2019s disease: subpopulation analysis of the TRAILBLAZER-ALZ 2 randomized trial. Neurol Ther. 2024;13(3):677\u201395.","journal-title":"Neurol Ther."},{"issue":"Suppl. 1","key":"2087_CR7","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1192\/bjo.2023.227","volume":"9","author":"S Salloway","year":"2023","unstructured":"Salloway S, Lee E, Papka M, et al. TRAILBLAZER-ALZ 4: topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer\u2019s disease [abstract]. BJPsych Open. 2023;9(Suppl. 1):S67.","journal-title":"BJPsych Open."},{"issue":"Suppl. 24","key":"2087_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082529","volume":"19","author":"A Pain","year":"2023","unstructured":"Pain A, Ferguson MB, Wang H, et al. TRAILBLAZER-ALZ 4: directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer\u2019s disease - results from 12-months [abstract]. Alzheimer\u2019s Dement. 2023;19(Suppl. 24): e082529.","journal-title":"Alzheimer's Dement"}],"updated-by":[{"DOI":"10.1007\/s40265-024-02103-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02087-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02087-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02087-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T15:06:51Z","timestamp":1729955211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02087-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2087"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02087-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"15 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-024-02103-7","URL":"https:\/\/doi.org\/10.1007\/s40265-024-02103-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}